HPV research priorities: new and future directions
Sunday, December 2, 2018
Main Training Course
•
MTC 04
•
4:00 PM
>
6:00 PM
•
HPV research priorities: new and future directions
•
Auditorium I
With growing knowledge, etiologic evidence and more advanced molecular technologies, several important HPV research priorities emerge as critical for future studies. Cutting-edge molecular studies and large-scale next-generation sequencing efforts have provided unique insights into HPV carcinogenesis, the role of both human and viral genetic variation in carcinogenesis, and the interaction between the host and the virus, and may identify potential biomarkers of significant infection or new therapeutic targets.
4:00 PM
•
MTC 04-01
•
Population-based assessment of HPV genotype-specific cervical cancer survivors : CDC cancer registry sentinel surveillance system
>
M.
Marc
Goodman
4:12 PM
•
MTC 04-02
•
Characterization of cervical pre-cancers and cancers with and without HPV integration
>
J.
Joseph
BOLAND
4:24 PM
•
MTC 04-03
•
Molecular characterization of HPV16 sublineages: viral sequences, integration events, and human somatic mutation landscape
>
M.
Michael
DEAN
4:36 PM
•
MTC 04-04
•
Safety and efficacy of prophylactic HPV vaccines. A Cochrane review of randomised trials
>
M.
Marc
ARBYN
4:48 PM
•
MTC 04-05
•
Small molecule inhibitors of HPVs : an overview
>
T.
Thomas R
Broker
5:00 PM
•
MTC 04-06
•
Nine years of the Scottish HPV archive - A resource support for basic and applied HPV research
>
E.
Elia
Alcañiz Boada
5:12 PM
•
MTC 04-07
•
A Danish clinical cervical cytology biobank. Pilot studies of sample processing and quality
>
D.
Dorthe
Oernskov
5:24 PM
•
MTC 04-08
•
RNA sequencing of human papillomavirus negative invasive cervical cancers
>
C.
Camilla
Lagheden
5:36 PM
•
MTC 04-09
•
Is HPV-negative cervical cancer a biologically different entity?
>
M.
Miriam
ELFSTRÖM
5:48 PM
•
MTC 04-10
•
Discussion
|